Project Grant R21AI196972
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a Project Grant totaling $810,181 to the University of California Santa Cruz on April 20, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). This award supports a five-year research initiative (concluding March 31, 2031) investigating how bacterial pathogens sense and respond to host environmental cues—specifically iron availability and oxidative stress—to regulate...
- Federal Grant Award Summary The University of California, San Diego received a $449,578 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), with an award date of February 1, 2026, and completion date of January 31, 2031. This five-year award supports investigator-initiated biomedical research exploring the role of lytic polysaccharide monooxygenases (LPMOs) in the virulence and immunity...
- Federal Grant Award Summary The University of California, Santa Barbara received a $410,497 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective July 1, 2025 through June 30, 2027. The research project investigates Type 5 secretion as a novel mechanism for delivering protein effectors directly into mammalian host cells, with a specific focus on filamentous hemagglutinin-like...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $431,004 Project Grant to the University of California, Davis under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 18, 2025, with a completion date of June 30, 2027. This award supports biomedical research investigating the mechanistic interplay between human cells and Entamoeba histolytica, a pathogenic amoeba that causes amoebiasis. The research project,...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $438,500 Project Grant to the University of California, San Diego under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 8, 2025, with a completion date of June 30, 2027. This award funds investigator-initiated biomedical research examining the sequence-specific determinants and impacts of NS2 (nonstructural protein 2) interactions with the Influenza A Virus...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $416,005 Project Grant to the University of California Santa Cruz under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective August 15, 2025, with a completion date of July 31, 2027. This award funds research to establish the structural and molecular basis for human astrovirus (HAstV) entry into human cells, with the ultimate objective of identifying functional sites on...
- Federal Grant Award Summary The University of California, Merced received a $647,181 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective February 1, 2026 through January 31, 2031. The award supports fundamental biomedical research aimed at elucidating the regulatory mechanisms governing inflammasome assembly and activity. Inflammasomes are multiprotein complexes that play...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of California, Davis a Project Grant totaling $744,328 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on February 13, 2026. The research will be conducted through January 31, 2031 at UC Davis's campus in Davis, California. This award supports investigator-initiated biomedical research examining the role of trogocytosis (a cell-nibbling mechanism) in the...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $492,000 to The Regents of the University of California, San Francisco under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 1, 2025, for a five-year project period concluding July 31, 2030. The award funds biochemical and structural characterization research of the elongasome and divisome protein complexes in Mycobacterium tuberculosis (MTB) and the...
- Federal Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of California, San Diego a $3.19 million Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 16, 2025, with a completion date of June 30, 2029. This grant funds investigator-initiated biomedical research examining the roles and regulation of tissue-resident CD8 T cells during persistent viral infection, utilizing the lymphocytic...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of California Santa Cruz a $430,375 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period April 2, 2026 through March 31, 2028. This award supports investigator-initiated research exploring the bacterial polyadenylase PAP I as a potential antimicrobial drug target. The project delivers scientific research services aimed at understanding how polyadenylation of ribonucleic acid (RNA) transcripts contributes to antimicrobial resistance and bacterial pathogenesis in clinically significant pathogens including Yersinia pseudotuberculosis, Shigella flexneri, Klebsiella pneumoniae, and Salmonella enterica. The research deliverables include characterization of PAP I's role in maintaining virulence and resistance plasmids, assessment of PAP I's contribution to antimicrobial resistance and cellular stress resistance mechanisms, and identification of the polyadenylation landscape in pathogenic Enterobacteriaceae species. The project generates knowledge intended to advance antimicrobial drug development by establishing PAP I as a viable therapeutic target. Research activities will be conducted at UC Santa Cruz's Santa Cruz, California facility, positioning the institution as the primary research performer under this NIAID-funded initiative.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $430.4k | 4/2/26 |